

LAC DPH COVID-19 Update:

Booster Doses—Correction and Resources



oses

r or Moderna

g-term care settings

or Moderna as their primary 2-dose be any COVID-19 vaccine (J&J, Pfizer, or the risks and benefits of a booster, if a

to COVID-19 because of their work

Booster Dose Any COVID-19 vacci Booster Dose Any COVID-19 vac

Public Health

This message was originally sent on 10/23/21. It is being re-issued with a correction and updates.

This message is intended for all healthcare providers in Los Angeles County. Please distribute as appropriate.

Correction and New Resources

Correction

The COVID-19 Vaccine Update that was issued on October 23 contained an error in the Moderna COVID-19 vaccine booster dose. The correct dose is 50 µg in 0.25 ml (not 0.25 mg). This has been corrected in the original LAHAN below and <u>online</u>.

LAC DPH Booster Resources

- The LAC DPH COVID-19 Vaccine Eligibility Summary tables for providers and patients have been updated to include that immunocompromised individuals who have received a 3rd dose of mRNA vaccine may receive a booster dose at least 6 months after their 3rd dose.
- Two new patient infographics are now available: <u>Booster Doses</u> and <u>Doses for People Who</u> <u>Are Immunocompromised</u>. There is also a two-page <u>combined infographic</u>.

Primary Series was Pfizer or Mode	na	Prima	ry Series
An additional (1 th) does of mRNA vaccine is recommended for people with wakened immune systems. The CDC recommends that moderately to severely immunocompromised people Piter or Moderna receive a 3 th does. This includes people who have: Been receiving active cancer treatment for tumnors or cancers of the bloo • Received an organ transplant and are taking medicine to suppress the ir Received as the cell transplant within the last 2 yeas or are taking in Received as the cell transplant within the last 2 yeas or are taking in	whose primary series was mmune system	Everyone who received dose. This includes peop may be any COVID-19 ver the risks and benefits of a Dose 1 At les	ole with moder ccines (J&J, Pfi
immune system Moderate or severe primary immunodeficiency (such as DiGeorge syn syndrome) Advanced or untreated HIV infection Active treatment with high-dose corticosteroids or other drugs that mu response		J&J primary series	rimary S
This 3rd does should be the same COVID-19 vectore as your primary series. Taik need to get an additional does of COVID-19 vectores and about the best timin treatment plan. This is especially important if you are about to start or restart immur A booster dose may be considered at least 6 months after receiving the additio. any COVID-19 vectore.	g based on your current iosuppressive treatment.	Booster doses are for series who meet certain Moderna). Talk to your booster is right for you, c	people who n conditions. doctor if you
Pfizer - Additional dose should be Pfizer Dose 1 Dose 2 Additional (3**) Dose 21 days 28+ days 4 Additional (3**) Dose Pfizer primary prices Pfizer	Booster Dose	People who should get	5 years and old 8 years and old 0-64 years who ay get a boost 8-49 years with 8-64 years at h
Moderna – Additional dose should be Moderna		People with moderately after their additional (3 rd)	or severely we) dose. See Do
Dose 1 Dose 2 Additional (3 rd) Dose	Booster Dose	Pfizer	
At least 6 mon Moderna primary series Moderna	Any COVID-19 vaccine	Dose 1	Dose 2
Primary Series was Johnson & Johnso	n (J&J)	Pfizer primary s	eries
The CDC recommends that moderately to severely immunocomposited people all recive a board rokes. Tak to your door aboar the best timing based plan. This is expecially important if you are aboard to start or restart immunouppress Does 1 Booster Does At least 2 months	n your current treatment	Dose 1	Dose 2

Please see the original corrected LAHAN below.

Expanded Eligibility for COVID-19 Vaccine Booster Shots

After <u>authorization</u> by the Food and Drug Administration, the Centers for Disease Control and Prevention have <u>expanded the recommendations</u> for booster shots to include Moderna and Johnson and Johnson/Janssen (J&J) COVID-19 vaccines as well as heterologous (mix and match) dosing.

Key new CDC booster recommendations:

- All persons who received a J&J COVID-19 vaccine should get a single vaccine booster dose at least 2 months after their initial J&J dose. The booster can be J&J or either of the mRNA vaccines.
- **Certain people who received Moderna** for their primary series should receive a single vaccine booster dose **at least 6 months** after completing the series. The group of eligible persons is the same as for Pfizer and listed below. Note that the Moderna COVID-19 vaccine booster dose is a half dose (50 µg in 0.25 ml).
- Individuals may choose which of the 3 authorized vaccines they would like to receive if they are eligible for a booster dose.

Booster eligibility for individuals who received either Pfizer or Moderna primary COVID-19 vaccine series

- A booster is **recommended** for:
 - People 65 years and older
 - Residents of long-term care facilities
 - People age 50–64 years with an <u>underlying medical condition</u> or are at <u>risk of</u> <u>social inequities</u>
- A booster may be considered for:
 - People age 18-49 years with an <u>underlying medical condition</u>
 - People age 18-64 years who are at higher risk of COVID-19 exposure due to their occupational or institutional setting; this includes all essential workers.

These recommendations have been endorsed by the <u>Western States Scientific Safety</u> <u>Review Workgroup</u>.

Upcoming CDC Booster Dose Resources

- The CDC is in the process of updating their COVID-19 vaccine <u>clinical</u> <u>considerations</u> and will be releasing an MMWR on the ACIP recommendations.
- The CDC is also hosting a live webinar for healthcare providers: What Clinicians Need to Know About the Recent Updates to CDC's Recommendations for COVID-19 Booster Vaccination Tuesday October 26. 11am-12 pm PST. Webinar details.

LAC DPH Booster Resources

- For providers: <u>COVID-19 Vaccine Eligibility Summary Table</u>. This table summarizes vaccine eligibility based on the primary series received and the patient age and/or risk factors.
- For patients: <u>Booster Dose How to Get Vaccinated</u> webpages (English and Spanish); a COVID-19 Vaccine Eligibility Summary Table in <u>English</u> and <u>Spanish</u>; updated patient vaccine FAQs in <u>English</u>. The <u>www.VaccinateLACounty.com</u> website hosts all COVID-19 vaccine related resource for the public.

See the COVID-19 Vaccine Eligibility Summary Table for Healthcare Providers on the last page.

Visit the LAC DPH <u>COVID-19 Provider Hub</u> and <u>Vaccination Hub</u> Refresh your browser to view the latest version.

This communication was sent by Claire Jarashow, Director, Vaccine Preventable Disease Control Program, Los Angeles County Department of Public Health



This table summarizes COVID-19 vaccine eligibility based on the primary series received and the patient age and/or risk factors. The most current version of this table is available <u>online</u>.

Vaccine	Dose	Age			
		12-17	18-49	50-64	65+
Pfizer/ Comirnaty & Moderna ¹	Primary 2-dose series	Pfizer only	\checkmark	~	~
	Third dose ("additional dose") ² recommended for moderate to severely immunocompromised persons at least 28 days after 2 nd dose	Pfizer only	✓	✓	~
	Booster dose ³ recommended at least 6 months after primary series ⁴ if the individual:				~
	• Resides in a long-term care facility		\checkmark	✓	
	 Has underlying <u>medical condition</u> or increase risk of <u>social inequities</u> 		May receive	~	
	 Has increased risk of exposure from work or institutional setting 		May receive	May receive	
	 Is moderately to severely <u>immunocompromised</u>⁴ 		May receive	May receive	May receive
Janssen/	Primary single-dose series		\checkmark	\checkmark	✓
Johnson & Johnson (J&J)	Booster dose recommended ^{3,5} at least 2 months after the 1 st dose		~	~	~

^{1.} Moderna has two dose volumes. The full dose (100 μg in 0.5 ml) is authorized for both the primary series and the 3rd dose for persons who are immunocompromised (IC). A half dose (50 μg in 0.25 ml) is authorized for booster doses.

^{2.} The third dose of mRNA vaccine should be the same vaccine product as the primary series, whenever possible.

- 3 Booster doses can be the same vaccine as was given in the primary series or it can be a mix-and-match dose. Note: a Moderna booster dose is a half dose (50 μg in 0.25 ml).
- ^{4.} Those who have had a 3rd dose of mRNA vaccine due to IC *may receive* a booster dose \geq 6 months after their 3rd dose. If a Moderna vaccine is used, it should be the booster dose and volume (50 µg in 0.25 ml).
- ^{5.} All persons who received J&J as their primary dose should get a booster dose (including those who are IC at least 2 months (8 weeks) later. IC persons who received one primary dose of J&J should not receive more than two COVID-19 vaccines in total-if Moderna is used, it should be the half-dose.

For more information, see CDC <u>Clinical Considerations for Use of COVID-19 Vaccines</u>

